AstraZeneca wins FDA approval for SAPHNELO autoinjector pen for lupus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage
April 28, 2026 4:00 PM EDTAstraZeneca (NASDAQ: AZN) reports first-quarter results on Wednesday, with analysts expecting a solid but unexciting print, as investor focus shifts firmly toward a busy second-half pipeline newsflow that Bank of America says could drive a meaningful re-rating of the stock.
BofA analyst Sachin Jain said in a preview note released at the start of April... More
